Yes I am aware of Starpharma’s DEP technology and no we have not considered it at this stage to improve drug delivery to the cancer site. The reason why is we know Bisantrene can reach the cancer as it was historically formulated. If we want to make use of the 505(b)(2) pathway to approval we have to stick to the historical formulation.
Improvements in delivery are something that you work on after you have done your approval trials. This extends patent life and value.
Improving efficacy and reducing side effects, page-4
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.44 |
Change
0.040(2.86%) |
Mkt cap ! $245.3M | |||
| Open | High | Low | Value | Volume |
| $1.45 | $1.49 | $1.41 | $101.7K | 69.88K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9216 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.47 | 7767 | 2 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |